Emtriva Generic Name & Formulations
Emtricitabine 200mg; caps.
Nucleoside analogue (reverse transcriptase inhibitor).
HIV-1 infection, in combination with other antiretroviral agents.
Emtriva Dosage and Administration
≥18yrs: 200mg once daily. Renal impairment (CrCl 30–49mL/min): 200mg every 48hrs; (CrCl 15–29mL/min): 200mg every 72hrs; (CrCl <15mL/min or dialysis): 200mg every 96hrs.
<3mos: use oral soln. 3mos–17yrs (≤33kg): use oral soln; (>33kg): 200mg once daily. Renal impairment: reduce dose or prolong dosing interval (see full labeling).
Emtriva Boxed Warnings
Posttreatment exacerbation of hepatitis B.
Not for treating chronic HBV infection; test for HBV before starting therapy and closely monitor patients co-infected with HBV and HIV for several months after stopping treatment (discontinuing therapy may exacerbate HBV infection); if appropriate, initiate anti-hepatitis B therapy may be warranted. Suspend therapy if lactic acidosis or hepatotoxicity (eg, hepatomegaly, steatosis) occurs. Renal impairment. Pregnancy (Cat.B). Nursing mothers: not recommended.
Avoid concomitant drugs that contain emtricitabine or lamivudine (eg, fixed dose combination products).
Emtriva Adverse Reactions
Headache, diarrhea, nausea, fatigue, dizziness, depression, insomnia, abnormal dreams, rash, abdominal pain, asthenia, increased cough, rhinitis; new onset or worsening renal impairment, immune reconstitution syndrome; also children: skin hyperpigmentation.
Emtriva Clinical Trials
Register pregnant patients exposed to emtricitabine by calling (800) 258-4263.
Emtriva Patient Counseling